RATIONALE: The etiology and pathogenesis of angiogenesis in idiopathic pulmonary fibrosis (IPF) is poorly understood. Inter-alpha-trypsin inhibitor (IaI) is a serum protein that can bind to hyaluronan (HA) and may contribute to the angiogenic response to tissue injury. OBJECTIVES: To determine whether IaI promotes HA-mediated angiogenesis in tissue injury. METHODS: An examination was undertaken of angiogenesis in IaI-sufficient and -deficient mice in the bleomycin model of pulmonary fibrosis and in angiogenesis assays in vivo and in vitro. IaI and HA in patients with IPF were examined. MEASUREMENTS AND MAIN RESULTS: IaI significantly enhances the angiogenic response to short-fragment HA in vivo and in vitro. lal deficiency Ieads to decreased angiogenesis in the matrigel model, and decreases lung angiogenesis after bleomycin exposure in mice. IaI is found in fibroblastic foci in IPF, where it colocalizes with HA. The colocalization is particularly strong in vascular areas around fibroblastic foci. Serum levels of IaI and HA are significantly elevated in patients with IPF compared with control subjects. High serum IaI and HA levels are associated with decreased lung diffusing capacity, but not FVC. CONCLUSIONS: Our findings indicate that serum IaI interacts with HA, and promotes angiogenesis in lung injury. IaI appears to contribute to the vascular response to lung injury and may lead to aberrant angiogenesis. Clinical trial registered with www.clinicaltrials.gov (NCT00016627).
RATIONALE: The etiology and pathogenesis of angiogenesis in idiopathic pulmonary fibrosis (IPF) is poorly understood. Inter-alpha-trypsin inhibitor (IaI) is a serum protein that can bind to hyaluronan (HA) and may contribute to the angiogenic response to tissue injury. OBJECTIVES: To determine whether IaI promotes HA-mediated angiogenesis in tissue injury. METHODS: An examination was undertaken of angiogenesis in IaI-sufficient and -deficient mice in the bleomycin model of pulmonary fibrosis and in angiogenesis assays in vivo and in vitro. IaI and HA in patients with IPF were examined. MEASUREMENTS AND MAIN RESULTS: IaI significantly enhances the angiogenic response to short-fragment HA in vivo and in vitro. lal deficiency Ieads to decreased angiogenesis in the matrigel model, and decreases lung angiogenesis after bleomycin exposure in mice. IaI is found in fibroblastic foci in IPF, where it colocalizes with HA. The colocalization is particularly strong in vascular areas around fibroblastic foci. Serum levels of IaI and HA are significantly elevated in patients with IPF compared with control subjects. High serum IaI and HA levels are associated with decreased lung diffusing capacity, but not FVC. CONCLUSIONS: Our findings indicate that serum IaI interacts with HA, and promotes angiogenesis in lung injury. IaI appears to contribute to the vascular response to lung injury and may lead to aberrant angiogenesis. Clinical trial registered with www.clinicaltrials.gov (NCT00016627).
Authors: L Zhuo; M Yoneda; M Zhao; W Yingsung; N Yoshida; Y Kitagawa; K Kawamura; T Suzuki; K Kimata Journal: J Biol Chem Date: 2001-01-05 Impact factor: 5.157
Authors: Priit Teder; R William Vandivier; Dianhua Jiang; Jiurong Liang; Lauren Cohn; Ellen Puré; Peter M Henson; Paul W Noble Journal: Science Date: 2002-04-05 Impact factor: 47.728
Authors: Elisabetta A Renzoni; David A Walsh; Michael Salmon; Athol U Wells; Piersante Sestini; Andrew G Nicholson; Srihari Veeraraghavan; Anne E Bishop; Hanna M Romanska; Panagiotis Pantelidis; Carol M Black; Roland M Du Bois Journal: Am J Respir Crit Care Med Date: 2002-10-03 Impact factor: 21.405
Authors: M P Keane; J A Belperio; M D Burdick; J P Lynch; M C Fishbein; R M Strieter Journal: Am J Respir Crit Care Med Date: 2001-12-15 Impact factor: 21.405
Authors: Stavros Garantziotis; John W Hollingsworth; Rami B Ghanayem; Sarah Timberlake; Lisheng Zhuo; Koji Kimata; David A Schwartz Journal: J Immunol Date: 2007-09-15 Impact factor: 5.422
Authors: A Günther; B Enke; P Markart; P Hammerl; H Morr; J Behr; G Stähler; W Seeger; F Grimminger; I Leconte; S Roux; H-A Ghofrani Journal: Eur Respir J Date: 2007-01-10 Impact factor: 16.671
Authors: Carol S Trempus; Rebecca J Morris; Carl D Bortner; George Cotsarelis; Randall S Faircloth; Jeffrey M Reece; Raymond W Tennant Journal: J Invest Dermatol Date: 2003-04 Impact factor: 8.551
Authors: Jeremy Herrera; Colleen Forster; Thomas Pengo; Angeles Montero; Joe Swift; Martin A Schwartz; Craig A Henke; Peter B Bitterman Journal: JCI Insight Date: 2019-01-10
Authors: Long Zhu; Lisheng Zhuo; Koji Kimata; Etsuro Yamaguchi; Hideto Watanabe; Mark A Aronica; Vincent C Hascall; Kenji Baba Journal: Int Arch Allergy Immunol Date: 2010-05-18 Impact factor: 2.749
Authors: Carol S Trempus; Weifeng Song; Ahmed Lazrak; Zhihong Yu; Judy R Creighton; Bethany M Young; Rebecca L Heise; Yen Rei Yu; Jennifer L Ingram; Robert M Tighe; Sadis Matalon; Stavros Garantziotis Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-05-04 Impact factor: 5.464
Authors: Souheil El-Chemaly; Daniela Malide; Enrique Zudaire; Yoshihiko Ikeda; Benjamin A Weinberg; Gustavo Pacheco-Rodriguez; Ivan O Rosas; Marta Aparicio; Ping Ren; Sandra D MacDonald; Hai-Ping Wu; Steven D Nathan; Frank Cuttitta; J Philip McCoy; Bernadette R Gochuico; Joel Moss Journal: Proc Natl Acad Sci U S A Date: 2009-02-23 Impact factor: 11.205